Publications by authors named "Barbara Dreta"

Claim this Profile
E
Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study.
Inga Mandac Smoljanović, Igor Aurer, Nikola Bulj, Barbara Dreta, Antonija Miljak

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib in relapsed/refractory multiple myeloma patients - real world evidence - experiences of the Croatian cooperative group for hematologic diseases (KROHEM).
Davor Galusic, Josip Batinic, Ivan Krecak, Barbara Dreta, Delfa Radic Kristo

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).
Josip Batinić, Barbara Dreta, Goran Rinčić, Antonia Mrdeža, Karla Mišura Jakobac

Medicina (Kaunas)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL.
Thomas Chatzikonstantinou, Lydia Scarfò, Eva Minga, Georgios Karakatsoulis, Dimitra Chamou, Barbara Dreta

Hemasphere· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP).
Ida Hude Dragičević, Sandra Bašić-Kinda, Helena Markotić, Martina Morić-Perić, Dino Dujmović, Barbara Dreta

Medicina (Kaunas)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Thomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, Eva Minga, Dimitra Chamou, Barbara Dreta

EClinicalMedicine· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Zdravko Mitrovic, Dino Dujmovic, Ozren Jaksic, Sandra Basic Kinda, Petar Gacina, Barbara Dreta

Eur J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.
Davor Galusic, Sandra Basic-Kinda, Andela Pijuk, Vibor Milunovic, Barbara Dreta

Hemasphere· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases.
Sandra Bašić-Kinda, Karla Mišura Jakobac, Jasminka Sinčić-Petričević, Dajana Deak, Marijo Vodanović, Barbara Dreta

Croat Med J· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis